Nalbuphine Sedation in a Patient with Long Term, High Dose Chemotherapeutically Controlled Psychosis
Identifieur interne : 007C21 ( Ncbi/Curation ); précédent : 007C20; suivant : 007C22Nalbuphine Sedation in a Patient with Long Term, High Dose Chemotherapeutically Controlled Psychosis
Auteurs : Maureen Kelly ; Robert M. HowellSource :
- Anesthesia Progress [ 0003-3006 ] ; 1985.
Abstract
Consideration of which pharmacologic agent to use when a patient requires sedation prior to an oral surgery procedure entails a number of factors, including past medical history, current medications and dose level, duration of administration, pharmacologic interactions, and the dental needs of the patient. The case described in this report illustrates the importance of consideration of these factors in a patient who required sedation prior to oral surgery while taking 800 mg chlorpromazine, 300 mg amantadine hydrochloride, and 900 mg of cimetidine daily. The possible pharmacologic interactions which could occur from concomitantly administering either diazepam or a narcotic in the presence of these agents are numerous and significant. The choice of sedative agent was further complicated by the fact that the patient was prescribed chlorpromazine and amantadine in doses which far exceeded the usual therapeutic levels and had been maintained for an extended period of time, over 8 months. Consequently, any adverse reactions that may have resulted when sedating a patient taking chlorapromazine and amantadine hydrochloride in lower doses for a shorter duration would be more likely to occur with greater speed and severity in a patient receiving such high-dose, long-term therapy. Also, unusual reactions which have not been reported with usual therapeutic dose levels might also occur since these high doses approach toxic levels for some patients. Additionally, a sedative agent had to be used which would not interfere with the antipsychotic effects of chlorpromazine since the patient's psychiatric condition required maintenance of these unusually high therapeutic levels. The following case report gives the rationale and outcome of utilizing nalbuphine for obtunding pain and producing sedation during an oral surgery procedure under such complex therapeutic conditions.
Url:
PubMed: 3866505
PubMed Central: 2175415
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E69
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000E69
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002959
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :007C21
Links to Exploration step
PMC:2175415Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nalbuphine Sedation in a Patient with Long Term, High Dose Chemotherapeutically Controlled Psychosis</title>
<author><name sortKey="Kelly, Maureen" sort="Kelly, Maureen" uniqKey="Kelly M" first="Maureen" last="Kelly">Maureen Kelly</name>
</author>
<author><name sortKey="Howell, Robert M" sort="Howell, Robert M" uniqKey="Howell R" first="Robert M." last="Howell">Robert M. Howell</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">3866505</idno>
<idno type="pmc">2175415</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2175415</idno>
<idno type="RBID">PMC:2175415</idno>
<date when="1985">1985</date>
<idno type="wicri:Area/Pmc/Corpus">000E69</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E69</idno>
<idno type="wicri:Area/Pmc/Curation">000E69</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000E69</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002959</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002959</idno>
<idno type="wicri:Area/Ncbi/Merge">007C21</idno>
<idno type="wicri:Area/Ncbi/Curation">007C21</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Nalbuphine Sedation in a Patient with Long Term, High Dose Chemotherapeutically Controlled Psychosis</title>
<author><name sortKey="Kelly, Maureen" sort="Kelly, Maureen" uniqKey="Kelly M" first="Maureen" last="Kelly">Maureen Kelly</name>
</author>
<author><name sortKey="Howell, Robert M" sort="Howell, Robert M" uniqKey="Howell R" first="Robert M." last="Howell">Robert M. Howell</name>
</author>
</analytic>
<series><title level="j">Anesthesia Progress</title>
<idno type="ISSN">0003-3006</idno>
<imprint><date when="1985">1985</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Consideration of which pharmacologic agent to use when a patient requires sedation prior to an oral surgery procedure entails a number of factors, including past medical history, current medications and dose level, duration of administration, pharmacologic interactions, and the dental needs of the patient. The case described in this report illustrates the importance of consideration of these factors in a patient who required sedation prior to oral surgery while taking 800 mg chlorpromazine, 300 mg amantadine hydrochloride, and 900 mg of cimetidine daily. The possible pharmacologic interactions which could occur from concomitantly administering either diazepam or a narcotic in the presence of these agents are numerous and significant. The choice of sedative agent was further complicated by the fact that the patient was prescribed chlorpromazine and amantadine in doses which far exceeded the usual therapeutic levels and had been maintained for an extended period of time, over 8 months. Consequently, any adverse reactions that may have resulted when sedating a patient taking chlorapromazine and amantadine hydrochloride in lower doses for a shorter duration would be more likely to occur with greater speed and severity in a patient receiving such high-dose, long-term therapy. Also, unusual reactions which have not been reported with usual therapeutic dose levels might also occur since these high doses approach toxic levels for some patients. Additionally, a sedative agent had to be used which would not interfere with the antipsychotic effects of chlorpromazine since the patient's psychiatric condition required maintenance of these unusually high therapeutic levels. The following case report gives the rationale and outcome of utilizing nalbuphine for obtunding pain and producing sedation during an oral surgery procedure under such complex therapeutic conditions.</p>
</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV2/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007C21 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 007C21 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= EdenteV2 |flux= Ncbi |étape= Curation |type= RBID |clé= PMC:2175415 |texte= Nalbuphine Sedation in a Patient with Long Term, High Dose Chemotherapeutically Controlled Psychosis }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:3866505" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a EdenteV2
![]() | This area was generated with Dilib version V0.6.32. | ![]() |